Medical Professionals Reference (MPR)Intranasal Epinephrine Shows High Efficacy in Real-World Anaphylaxis Management

Real-world data from 55 patients across 8 allergy practices found 92.3% achieved symptom resolution with a single dose of intranasal epinephrine (neffy). Indicated for patients aged 4 and older weighing at least 15 kg, the nasal spray may reduce dangerous administration delays caused by needle phobia in pediatric anaphylaxis.

🔬 Clinical Considerations

• Single-dose resolution in 92.3% of cases positions intranasal epinephrine as clinically comparable to IM epinephrine for allergic office reactions and food challenges
• Needle phobia causes documented delays in epinephrine administration by parents and staff; neffy’s simpler delivery may prompt earlier intervention
• Intranasal absorption may be compromised by severe nasal congestion, deviated septum, or nasal polyps, limiting suitability for some pediatric patients
• Most patients carrying autoinjectors cannot correctly demonstrate proper technique; neffy’s single-nostril administration reduces user error under stress

🎯 Practice Applications

• Discuss intranasal epinephrine as an option for needle-averse pediatric patients and families at allergy visits
• Screen patients for anatomical contraindications (polyps, severely deviated septum) before prescribing neffy
• Confirm weight eligibility (15 kg minimum) and age (4 years and older) before prescribing
• Train families that a second dose goes in the same nostril if symptoms persist

More in Anaphylaxis/Allergic Reactions